pharmaphorum October 25, 2024
A pair of artificial intelligence algorithms from Boston Scientific and Medtronic can be used by the NHS to monitor heart failure patients with implantable devices, but two others from Biotronik and Abbott Medical have not passed muster.
The algorithms are designed to detect the early signs of worsening heart failure in people with CIEDs – pacemakers, implantable cardioverter defibrillators, and cardiac resynchronisation therapy devices – and send an alert to the care team.
Updated guidance from health technology assessment (HTA) agency NICE has concluded that Boston Scientific’s HeartLogic and Medtronic’s TriageHF diagnostics are “options for algorithm-based remote monitoring in people with cardiac implantable electronic devices (CIEDs) who have heart failure,” provided they are used by specialist care teams.
Biotronik’s HeartInsight...
Today's Sponsors
Today's Sponsor